Chrome Plugin Live! Redefine the way you read FinTwit 🚀 Install Now
Quote Panel
Key Metrics
Fundamentals
Relative Strength
PSTV
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|
Forecast
Analyst rating
Last analyst upgrade/downgrade
Earnings Growth
YoY
Current
Estimates
Q2.23
N/A
-0.59
vs -3.60
Q3.23
N/A
-1.00
vs -2.85
Q4.23
N/A
-0.70
vs -2.40
Q1.24
N/A
-0.75
vs -2.10
Q2.24
N/A
-0.71
vs -0.59
Q3.24
N/A
-0.46
vs -1.00
Q4.24
N/A
-0.67
vs -0.70
Q1.25
N/A
-0.56
vs -0.75
Q2.25
N/A
-0.19
vs -0.71
Q3.25
N/A
-0.20
vs -0.46
Sales Growth
YoY
Current
Estimates
Q2.23
NA
1.9M vs NA
Q3.23
NA
1.2M vs NA
Q4.23
+486%
1.3M vs 224K
Q1.24
NA
1.7M vs NA
Q2.24
-31%
1.3M vs 1.9M
Q3.24
-100%
NA vs 1.2M
Q4.24
-100%
NA vs 1.3M
Q1.25
-37%
1.1M vs 1.7M
Q2.25
+16%
1.5M vs 1.3M
Q3.25
NA
1.8M vs NA
Return on Equity
QoQ
Q2.23
-56%
-0.56
vs -1.80
Q3.23
-123%
-1.23
vs -0.56
Q4.23
+283%
2.83
vs -1.23
Q1.24
+67%
0.67
vs 2.83
Q2.24
+39%
0.39
vs 0.67
Q3.24
+56%
0.56
vs 0.39
Q4.24
+44%
0.44
vs 0.56
Q1.25
+74%
0.74
vs 0.44
Institutionnal Ownership
QoQ
Q2.23
7
7
vs 21
-67%
Q3.23
12
12
vs 7
71%
Q4.23
12
12
vs 12
NA
Q1.24
10
10
vs 12
-17%
Q2.24
12
12
vs 10
20%
Q3.24
10
10
vs 12
-17%
Q4.24
10
10
vs 10
NA
Q1.25
16
16
vs 10
60%
globenewswire.com
7 hours ago
globenewswire.com
7 hours ago
zacks.com
13 hours ago
globenewswire.com
16 hours ago
Relative Strength
PSTV
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|
Forecast
533%2026-Revenue
44%2026-EPS
70%2026-EBITDA
Analyst rating
Strong Sell
Sell
Buy
Neutral
Strong Buy
Buy
Price Target
NaN(-100.00%)
Number of analyst
Last analyst upgrade/downgrade
No Data Available
Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer and other diseases. Its lead drug candidate is Rhenium-186 NanoLiposome, a patented radiotherapy that targets central nervous system cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. It has a license agreement with NanoTx, Corp. to develop and commercialize NanoTx's glioblastoma treatment. The company was formerly known as Cytori Therapeutics, Inc. and changed its name to Plus Therapeutics, Inc. in July 2019. Plus Therapeutics, Inc. was founded in 1996 and is headquartered in Austin, Texas.
NASDAQ
Unprofitable
Unprofitable
-0.01 ( -1.92%)
Relative Strenght
2
Volume Buzz
-85%
Earning Acce
No
Dist 52w H.
87%